Thierry Conroy

发表

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

S. Culine, T. Conroy, M. Ychou, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.

T. Gorlia, T. Conroy, E. Van Cutsem, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

T. Conroy, P. Laurent-Puig, M. Ychou, 2014, British Journal of Cancer.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

B. Chauffert, T. Conroy, M. Ducreux, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC

B. Chauffert, J. Pignon, T. Conroy, 2013, European journal of cancer.

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

T. Conroy, M. Ducreux, O. Bouché, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

L. Collette, T. Conroy, M. Namer, 1997, European journal of cancer.

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

T. Conroy, M. Ychou, J. Douillard, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.

T. Conroy, M. Ducreux, D. Peiffert, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive.

T. Conroy, D. Arsène, O. Bouché, 2008, Gastroenterologie clinique et biologique.

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

T. Conroy, M. Ychou, A. Kramar, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.

T. Conroy, P. Rougier, D. Wagener, 1996, European journal of cancer.

Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO.

T. Valentin, D. Pérol, E. Bompas, 2024, European journal of cancer.